文献速递白血病

急性髓系白血病逃逸T细胞靶向免疫治疗的机制

Escape from T-cell-targeting immunotherapies in acute myeloid leukemia.
PubMed 文献 · Blood · 2024-01-01

本综述聚焦急性髓系白血病(AML)对T细胞靶向免疫治疗(含检查点抑制剂)的耐药与逃逸机制。文中强调高干扰素γ信号AML亚群可从CD123×CD3双特异性双亲和力重定向分子及检查点抑制剂中获得临床获益,而对标准化疗反应可能性较低。综述还汇总T细胞耗竭与衰老、致癌信号降低AML细胞对T细胞杀伤易感性、I型与II型干扰素在抗肿瘤免疫中的双重作用,并展望基于实体瘤经验操纵AML肿瘤微环境以克服耐药的策略。

要点

  • 高干扰素γ信号AML亚群可从CD123×CD3双特异性双亲和力重定向分子及检查点抑制剂获得临床获益,对标准化疗反应可能性较低。
  • AML肿瘤微环境中T细胞存在耗竭与衰老等低功能状态,是T细胞靶向免疫治疗耐药的重要环节。
  • 致癌信号机制可降低AML细胞对T细胞介导杀伤的易感性,I型与II型干扰素在抗肿瘤免疫中呈双重作用。

核心结论

  • 高干扰素γ信号AML亚群可从CD123×CD3双特异性双亲和力重定向分子及检查点抑制剂获得临床获益,而对标准化疗反应可能性较低;综述提出借鉴实体瘤经验操纵AML肿瘤微环境以克服检查点抑制剂及其他T细胞免疫治疗耐药的未来方向。

研究设计与样本

  • 综述,总结单细胞与空间多模态技术揭示的实体瘤微环境分子特征及其与免疫治疗反应和耐药的相关性,并汇总AML肿瘤微环境的高维免疫细胞组成与功能研究进展。

主要发现

  • 单细胞与空间多模态技术推动了实体瘤微环境分子特征及其与免疫治疗反应和耐药相关性的发现。
  • 高干扰素γ信号AML亚群可从CD123×CD3双特异性双亲和力重定向分子及检查点抑制剂获得临床获益,而对标准化疗反应可能性较低。
  • AML免疫效应状态包括T细胞耗竭与衰老,致癌信号机制可降低AML细胞对T细胞介导杀伤的易感性,I型与II型干扰素在抗肿瘤免疫中呈双重作用。

关键数值与推荐

  • 高干扰素γ信号AML亚群从CD123×CD3双特异性双亲和力重定向分子及检查点抑制剂获得临床获益,对标准化疗反应可能性较低。
  • AML免疫效应状态包括T细胞耗竭与衰老。
  • 致癌信号机制可降低AML细胞对T细胞介导杀伤的易感性。
  • I型与II型干扰素在抗肿瘤免疫中呈双重作用。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Single-cell and spatial multimodal technologies have propelled discoveries of the solid tumor microenvironment (TME) molecular features and their correlation with clinical response and resistance to immunotherapy. Computational tools are incessantly being developed to characterize tumor-infiltrating immune cells and to model tumor immune escape. These advances have led to substantial research into T-cell hypofunctional states in the TME and their reinvigoration with T-cell-targeting approaches, including checkpoint inhibitors (CPIs). Until recently, we lacked a high-dimensional picture of the acute myeloid leukemia (AML) TME, including compositional and functional differences in immune cells between disease onset and postchemotherapy or posttransplantation relapse, and the dynamic interplay between immune cells and AML blasts at various maturation stages. AML subgroups with heightened interferon gamma (IFN-γ) signaling were shown to derive clinical benefit from CD123×CD3-bispecific dual-affinity retargeting molecules and CPIs, while being less likely to respond to standard-of-care cytotoxic chemotherapy. In this review, we first highlight recent progress into deciphering immune effector states in AML (including T-cell exhaustion and senescence), oncogenic signaling mechanisms that could reduce the susceptibility of AML cells to T-cell-mediated killing, and the dichotomous roles of type I and II IFN in antitumor immunity. In the second part, we discuss how this knowledge could be translated into opportunities to manipulate the AML TME with the aim to overcome resistance to CPIs and other T-cell immunotherapies, building on recent success stories in the solid tumor field, and we provide an outlook for the future.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Vadakekolathu J, Rutella S. Escape from T-cell-targeting immunotherapies in acute myeloid leukemia. Blood. 2024. PMID: 37467496. doi:10.1182/blood.2023019961

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。